CAROLYN BRANTLY: Open Payments
NPI 1467125492 · SHREVEPORT, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,200 in 60 payments from 13 companies in 2025. Trend: 2023 $1,402 · 2024 $1,218 · 2025 $1,200
Food & beverage: $1,200
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 9 | $276 |
| ABBVIE INC. | 15 | $187 |
| Phathom Pharmaceuticals, Inc. | 2 | $153 |
| Novo Nordisk Inc | 6 | $102 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 6 | $91 |
| Lilly USA, LLC | 5 | $88 |
| PFIZER INC. | 4 | $67 |
| Amgen Inc. | 4 | $62 |
| Astellas Pharma US Inc | 3 | $54 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $49 |
Products named: VOQUEZNA, AIRSUPRA, BREZTRI, QULIPTA, JARDIANCE, MOUNJARO, OTEZLA, Veozah.
Industry payments across LA — which companies pay providers there.
